JP2022518251A5 - - Google Patents

Info

Publication number
JP2022518251A5
JP2022518251A5 JP2021542311A JP2021542311A JP2022518251A5 JP 2022518251 A5 JP2022518251 A5 JP 2022518251A5 JP 2021542311 A JP2021542311 A JP 2021542311A JP 2021542311 A JP2021542311 A JP 2021542311A JP 2022518251 A5 JP2022518251 A5 JP 2022518251A5
Authority
JP
Japan
Prior art keywords
pharmaceutical product
product according
hepatotoxicity
drug
interleukin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021542311A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022518251A (ja
JP7514846B2 (ja
Filing date
Publication date
Priority claimed from GBGB1900811.9A external-priority patent/GB201900811D0/en
Priority claimed from GBGB1907839.3A external-priority patent/GB201907839D0/en
Priority claimed from GB201915003A external-priority patent/GB201915003D0/en
Application filed filed Critical
Priority claimed from PCT/EP2020/051332 external-priority patent/WO2020152122A1/en
Publication of JP2022518251A publication Critical patent/JP2022518251A/ja
Publication of JP2022518251A5 publication Critical patent/JP2022518251A5/ja
Application granted granted Critical
Publication of JP7514846B2 publication Critical patent/JP7514846B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021542311A 2019-01-21 2020-01-21 肝毒性の治療 Active JP7514846B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB1900811.9 2019-01-21
GBGB1900811.9A GB201900811D0 (en) 2019-01-21 2019-01-21 Treatment of hepatotoxicity
GB1907839.3 2019-06-03
GBGB1907839.3A GB201907839D0 (en) 2019-06-03 2019-06-03 Treatment of hepatotoxicity
GB201915003A GB201915003D0 (en) 2019-10-17 2019-10-17 Treatment of hepatotoxicity
GB1915003.6 2019-10-17
PCT/EP2020/051332 WO2020152122A1 (en) 2019-01-21 2020-01-21 Treatment of hepatotoxicity

Publications (3)

Publication Number Publication Date
JP2022518251A JP2022518251A (ja) 2022-03-14
JP2022518251A5 true JP2022518251A5 (cg-RX-API-DMAC7.html) 2023-01-31
JP7514846B2 JP7514846B2 (ja) 2024-07-17

Family

ID=69190770

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021542311A Active JP7514846B2 (ja) 2019-01-21 2020-01-21 肝毒性の治療

Country Status (13)

Country Link
US (1) US11319368B2 (cg-RX-API-DMAC7.html)
EP (1) EP3914621A1 (cg-RX-API-DMAC7.html)
JP (1) JP7514846B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210138579A (cg-RX-API-DMAC7.html)
CN (1) CN113677706B (cg-RX-API-DMAC7.html)
AU (1) AU2020211695B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021014105A2 (cg-RX-API-DMAC7.html)
CA (1) CA3126322A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021001903A1 (cg-RX-API-DMAC7.html)
MX (1) MX2021008727A (cg-RX-API-DMAC7.html)
PH (1) PH12021551750A1 (cg-RX-API-DMAC7.html)
TW (1) TWI858005B (cg-RX-API-DMAC7.html)
WO (1) WO2020152122A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023537422A (ja) * 2020-08-13 2023-08-31 サンシャイン・レイク・ファーマ・カンパニー・リミテッド Il-11の抗体及びその使用
WO2023006765A1 (en) * 2021-07-26 2023-02-02 Boehringer Ingelheim International Gmbh Treatment and prevention of alcoholic liver disease
CN115068442A (zh) * 2021-09-13 2022-09-20 荣灿生物医药技术(上海)有限公司 核酸的纳米颗粒组合物、其制备方法和用途
GB202218388D0 (en) 2022-12-07 2023-01-18 Vvb Bio Pte Ltd GP130 antigen-binding molecules
GB202311050D0 (en) 2023-07-19 2023-08-30 Vvb Bio Pte Ltd GP130 antigen-binding molecules
GB202405551D0 (en) 2024-04-19 2024-06-05 Vvb Bio Pte Ltd Combination treatment
GB202408044D0 (en) 2024-06-06 2024-07-24 Vvb Bio Pte Ltd gp130 antigen-binding molecules
WO2026159121A1 (en) 2025-01-22 2026-07-30 VVB Bio Pte. Ltd. Bispecific molecules

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE318832T1 (de) 1990-06-11 2006-03-15 Gilead Sciences Inc Verfahren zur vervendung von nukleinsäureliganden
DE69535274T2 (de) 1994-12-22 2007-06-06 Genetics Institute, LLC, Cambridge Verwendung eines menschlichen interleukin-11 rezeptors
ES2093562B1 (es) 1995-05-26 1997-07-01 Univ Santiago Compostela Estabilizacion de sistemas coloidales mediante formacion de complejos ionicos lipido-polisacarido.
US6126933A (en) 1995-06-27 2000-10-03 Genetics Institute Methods of treating inflammatory bowel diseases by administering IL-11
US5679339A (en) 1995-06-27 1997-10-21 Keith; James Method of using IL-11 for treating spondyloarthropies
US6540993B1 (en) 1995-06-27 2003-04-01 Wyeth Method of treating inflammatory bowel disease using a topical formulation of IL-11
US6649192B2 (en) 1996-07-29 2003-11-18 Universidade De Santiago De Compostela Application of nanoparticles based on hydrophilic polymers as pharmaceutical forms
GB9702944D0 (en) 1997-02-13 1997-04-02 Univ Manchester Reducing fibrosis
GB9721961D0 (en) 1997-10-16 1997-12-17 Glaxo Group Ltd Novel molecules
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
CA2237915A1 (en) 1998-05-19 1999-11-19 Stephen Shaughnessy Osteoporosis treatment
US6953777B2 (en) 1999-03-11 2005-10-11 Genetics Indtitute LLC Use of interleukin-11 to prevent immune-mediated cytotoxicity
WO2000078336A1 (en) 1999-06-21 2000-12-28 Genetics Institute, Inc. Treatment of fibrosis by antagonism of il-13 and il-13 receptor chains
EP1235842A4 (en) 1999-10-15 2003-04-23 Univ Massachusetts Rna interference pathway genes as tools for targeted genetic interference
GB0021668D0 (en) 2000-09-04 2000-10-18 Smithkline Beecham Plc New use
CA2498931A1 (en) 2002-09-16 2004-03-25 Wyeth Delayed release formulations for oral administration of a polypeptide therapeutic agent and methods of using same
JP2007537716A (ja) 2003-12-16 2007-12-27 コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガナイゼイション サイトカイン結合ドメイン
WO2005070446A1 (en) 2004-01-15 2005-08-04 Scios Inc. Method for treating cardiac remodeling following myocardial injury
US20080300147A1 (en) 2004-03-26 2008-12-04 Nasser Chegini Detection and Treatment of Fibrotic Disorders
ES2309427T3 (es) 2004-08-27 2008-12-16 Conaris Research Institute Ag Secuencias de nucleotidos optimizidas que codifican para sgp130.
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
JP2009518418A (ja) 2005-12-06 2009-05-07 ワイス インターロイキン11組成物および使用法
WO2008050789A1 (en) 2006-10-27 2008-05-02 The New Industry Research Organization Use of interleukin-11 as therapeutic agent for heart disease
CA2703544C (en) 2007-10-26 2016-01-05 Manuel Baca Cytokine muteins
US8182814B2 (en) 2007-10-26 2012-05-22 Csl Limited Methods of treating inflammatory airway conditions by inhibition of IL-11 activity
US8518888B2 (en) 2008-10-14 2013-08-27 Csl Limited Method of treatment of gastrointestinal-type cancer with antagonistic antibodies to IL-11R
KR101133769B1 (ko) 2011-04-18 2012-04-09 한국생명공학연구원 신규한 옥사졸리딘계 및 인돌계 화합물, 이의 제조방법 및 이를 포함하는 약학 조성물
PT2953971T (pt) 2013-02-07 2023-05-02 Csl Ltd Proteínas de ligação à il-11r e suas utilizações
CN105073128A (zh) * 2013-04-03 2015-11-18 Ibc药品公司 用于诱导对疾病的免疫应答的组合疗法
EP4609911A3 (en) * 2015-09-24 2025-11-19 Sinew Pharma Inc. Compounds effective in treating hepatotoxicity and fatty liver diseases and uses thereof
CN105497893B (zh) 2015-12-10 2019-02-01 黑龙江省科学院高技术研究院 IL-11单克隆抗体在抑制PI3K/Akt信号通路中的应用
GB201522186D0 (en) 2015-12-16 2016-01-27 Singapore Health Services Pte Ltd And Nat University Of Singapore The Treatment of fibrosis
RU2016125115A (ru) 2016-06-23 2017-12-28 Федеральное государственное бюджетное учреждение науки Институт биологического приборостроения с опытным производством Российской Академии наук (ИБП РАН) Терапевтическое антитело, специфичное к интерлейкину-11, ингибирующее сигналирование через его рецептор, и способ его использования для лечения пациентов
GB201621431D0 (en) 2016-12-16 2017-02-01 Singapore Health Services Pte Ltd And Nat Univ Of Singapore The Decoy cytokine receptor
GB201621439D0 (en) 2016-12-16 2017-02-01 Singapore Health Services Pte Ltd And Nat Univ Of Singapore IL-11Ra Antibodies
US20180186871A1 (en) 2016-12-16 2018-07-05 Singapore Health Services Pte Ltd. Il-11 antibodies
RU2016151730A (ru) 2016-12-28 2018-06-29 Федеральное государственное бюджетное учреждение науки Институт биологического приборостроения с опытным производством Российской Академии наук (ИБП РАН) Антитела для лабораторной диагностики концентрации интерлейкина-11
GB201806918D0 (en) 2018-04-27 2018-06-13 Enleofen Bio Pte Ltd Combination treatment for eye fibrosis
GB201809699D0 (en) * 2018-06-13 2018-08-01 Singapore Health Serv Pte Ltd IL-11 antibodies
GB201809700D0 (en) 2018-06-13 2018-08-01 Singapore Health Serv Pte Ltd IL-11 antibodies

Similar Documents

Publication Publication Date Title
Yoon et al. Microglial NLRP3-gasdermin D activation impairs blood-brain barrier integrity through interleukin-1β-independent neutrophil chemotaxis upon peripheral inflammation in mice
Natoli et al. Microglia-derived IL-1β promotes chemokine expression by Müller cells and RPE in focal retinal degeneration
Müller et al. CXCR3 signaling reduces the severity of experimental autoimmune encephalomyelitis by controlling the parenchymal distribution of effector and regulatory T cells in the central nervous system
US9945870B2 (en) Methods for determining responsiveness to an anti-CD47 agent
US12269873B2 (en) Signature of TL1A (TNFSF15) signaling pathway
Tang et al. Forkhead box protein p1 is a transcriptional repressor of immune signaling in the CNS: implications for transcriptional dysregulation in Huntington disease
US10822406B2 (en) Method for treating chronic intestinal inflammation and inflammatory bowel disease by administering antagonists of Oncostatin-M (OSM) and/or antagonists of OSM receptor-beta (OSMR)
Selmi et al. Current trends in autoimmunity and the nervous system
JP2022521591A5 (cg-RX-API-DMAC7.html)
Strecker et al. Monocyte chemoattractant protein-1-deficiency impairs the expression of IL-6, IL-1β and G-CSF after transient focal ischemia in mice
JP6868655B2 (ja) Cd6結合パートナーの使用およびそれに基づく方法
Moran et al. The role of interleukin-17 in immune-mediated inflammatory myopathies and possible therapeutic implications
US20160000936A1 (en) Biomarkers for inflammatory disease and methods of using same
JP2010505878A (ja) 線維症の処置のためのccr2アンタゴニスト
Salvesen et al. LPS-induced systemic inflammation reveals an immunomodulatory role for the prion protein at the blood-brain interface
US20250334594A1 (en) Methods for the treatment of amyotrophic lateral sclerosis
Acharjee et al. Characterization of microglial transcriptomes in the brain and spinal cord of mice in early and late experimental autoimmune encephalomyelitis using a RiboTag strategy
JP2026027222A (ja) 潰瘍性大腸炎に関与する遺伝子の抗il-23p19抗体調節
AU2014352891B2 (en) Identification of a novel B cell cytokine
Gaunt et al. Cytokine enrichment in deep cerebellar nuclei is contributed by multiple glial populations and linked to reduced amyloid plaque pathology
Ding et al. Multi-targeted olink proteomics analyses of cerebrospinal fluid from patients with aneurysmal subarachnoid hemorrhage
Dohi et al. Acute stress transiently activates macrophages and chemokines in cervical lymph nodes
US20180267059A1 (en) Compositions and methods for treating age-related diabetes and related disorders
US20220162325A1 (en) Type i interferon-mediated disorders
US20220290239A1 (en) Biomarkers associated with anti-il-36r antibody treatment in generalized pustular psoriasis